GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

Revlar/Breo Ellipta sales declined 5%. The decline in vaccine sales was primarily due to lower sales of its RSV vaccine ...

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the ...